Muscarinic control of gallbladder dynamics. A study using 99 Tcm-HIDA and cholinergic agonists and antagonists

Elvira, J.M. Llamas; Sopena, R; Martínez-Paredes, M; Jiménez-Heffernan, Amelia; Fm, Gonzalez; Torres, Marta; Jm, Latre; Mateo, Annabelle R.

doi:10.1097/00006231-199011000-00011

Cited by 9 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These medical therapies, among others, have been evaluated in small proof of concept studies with some success. [16][17][18][19] That said, the data regarding these treatments are very limited and none have been adopted as a "gold standard" therapy. In addition, the experience of the authors in recommending medical treatment, even as part of a randomized controlled trial, was severely limited by the lack of an established "gold standard" medical treatment to offer.…”

Section: Medical Treatmentmentioning

confidence: 99%

Biliary Dyskinesia: Current Perspectives and Future Directions

Richmond

Walker

2020

The American Surgeon™

View full text Add to dashboard Cite

Biliary dyskinesia (BD) is a disorder characterized by functional biliary pain, the absence of gallstones on ultrasound, and the finding of a reduced gallbladder ejection fraction on a cholecystokinin-cholescintigraphic scan. Cholecystectomy remains a commonly applied treatment for BD, despite a lack of high-quality evidence supporting the practice. The following article provides an overview of the current diagnostic strategies, treatment outcomes with both surgical and nonsurgical treatment, emerging considerations related to special populations, and suggestions for addressing the identified knowledge gaps, moving forward in an effort to develop stronger, more evidence-based practice guidelines for treating this poorly understood and poorly studied condition.

show abstract

Section: Medical Treatmentmentioning

confidence: 99%

Biliary Dyskinesia: Current Perspectives and Future Directions

Richmond

Walker

2020

The American Surgeon™

View full text Add to dashboard Cite

show abstract

“…The block of M1 muscarinic receptors inhibits gastric acid production and also induces a significant delay in the emptying of the stomach [4,5]. Conflicting findings are reported on esophageal, biliary, and enteric motility [6][7][8][9][10], even though pirenzepine is also used in treatment of irritable bowel syndrome [11,12]. Interestingly, pirenzepine, at doses below 0.1 rag/ kg, has a bradycardic rather than a tachycardic effect.…”

mentioning

confidence: 99%

Usefulness and safety of pirenzepine in double-contrast study of upper gastrointestinal tract: Comparison with scopolamine methylbromide

et al. 1994

View full text Add to dashboard Cite

To evaluate usefulness of pirenzepine, a selective M1 antimuscarinic drug, for diagnostic double-contrast study of the upper gastrointestinal tract, pirenzepine and scopolamine methylbromide (SMB) were compared in a single blind randomized trial. Seventy consecutive patients were enrolled in the study. Artifacts, bowel distention, painting of stomach and duodenal bulb, and global quality of the images were blindly evaluated by four independent observers by means of a numerical score (1-4). Under SMB slightly but significantly better results for stomach were scored (3.1 +/- .7 vs. 2.7 +/- 7, p < 0.01). No differences were found in the study of the duodenal bulb. Heart rate and rhythm during the study were recorded by electrocardiogram (ECG). SMB induced tachycardia in all patients (from 77 +/- 20 to 117 +/- 28 beats/min, p < 0.01) while pirenzepine did not (from 77 +/- 16 to 81 +/- 23, p = NS). After SMB, two patients exhibited faintness, and some patients complained of visual accommodation defects, dryness of the mouth, and dizziness. Thus, pirenzepine provides good results in double-contrast studies (equal to SMB), while presenting no adverse effects. It could be proposed as a first choice hypotonic agent in upper gastrointestinal examination.

show abstract

Hepatobiliary Scintigraphy

Tülchinsky¹

2006

Diagnostic Nuclear Medicine

View full text Add to dashboard Cite

Muscarinic control of gallbladder dynamics. A study using 99 Tcm-HIDA and cholinergic agonists and antagonists

Cited by 9 publications

References 0 publications

Biliary Dyskinesia: Current Perspectives and Future Directions

Biliary Dyskinesia: Current Perspectives and Future Directions

Usefulness and safety of pirenzepine in double-contrast study of upper gastrointestinal tract: Comparison with scopolamine methylbromide

Hepatobiliary Scintigraphy

Contact Info

Product

Resources

About